Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: A case-control study in a high-risk region of China

Pharmacogenetics and Genomics

Volumn 16, Issue 3, 2006, Pages 219-227

  Chen, Xiaoping ^a,b   Wang, Haijian ^a,b,c   Xie, Weimin ^d   Liang, Renxiang ^e   Wei, Zhongliang ^e   Zhi, Lianteng ^a,b   Zhang, Xiumei ^b   Hao, Bingtao ^a   Zhong, Shaofei ^a   Zhou, Gangqiao ^a,b   Zhang, Lingqiang ^a   Gao, Xue ^a   Zhu, Yunping ^a   He, Fuchu ^a,b,c  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c FUDAN UNIVERSITY   (China)

^d Guangxi Cancer Institute   (China)

^e Fusui Cancer Institute   (China)

Author keywords

CYP1A2; Hepatocellular carcinoma; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 1A2; HEPATITIS B SURFACE ANTIGEN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINA; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK; SMOKING;

EID: 33644597573     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211.
2. Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 1997; 89:1844-1851.
3. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90 000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11:369-376.
4. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127:27-34.
5. Omer RE, Van't Veer P, Kadaru AM, Kampman E, el Khidir IM, Fedail SS, et al. The role of hepatitis B and hepatitis C viral infections in the incidence of hepatocellular carcinoma in Sudan. Trans R Soc Trop Med Hyg 2001; 95:487-491.
6. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339:943-946.
7. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 1997; 7:20-30.
8. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30:379-383.
9. Gallagher EP, Wienkers LC, Stapleton PL, Kunze KL, Eaton DL. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res 1994; 54:101-108.
10. Gallagher EP, Kunze KL, Stapleton PL, Eaton DL. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol Appl Pharmacol 1996; 141:595-606.
11. Mace K, Aguilar F, Wang JS, Vautravers P, Gomez-Lechon M, Gonzalez FJ, et al. Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 1997; 18:1291-1297.
12. Heinonen JT, Fisher R, Brendel K, Eaton DL. Determination of aflatoxin B1 biotransformation and binding to hepatic macromolecules in human precision liver slices. Toxicol Appl Pharmacol 1996; 136:1-7.
13. Doi AM, Patterson PE, Gallagher EP. Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme expression in human prenatal and adult liver. Toxicol Appl Pharmacol 2002; 181:48-59.
14. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 1995; 92:2384-2387.
15. Chen CJ, Yu MW, Liaw YF, Wang LW, Chiamprasert S, Matin F, et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 1996; 59:128-134.
16. Sun CA, Wang LY, Chen CJ, Lu SN, You SL, Wang LW, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001; 22:1289-1294.
17. McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, et al. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 2003; 63:4594-4601.
18. Deng ZL, Wei YP, Ma Y. Polymorphism of glutathione S-transferase mu 1 and theta 1 genes and hepatocellular carcinoma in southern Guangxi, China. World J Gastroenterol 2005; 11:272-274.
19. Sofowora GG, Choo EF, Mayo G, Shyr Y, Wilkinson GR. In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 2001; 47:505-510.
20. Guillouzo A. Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res 1995; 55:5574-5579.
21. Wang JS, Huang T, Su J, Liang F, Wei Z, Liang Y, et al. Hepatocellular carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2001; 10:143-146.
22. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G → T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993; 90:8586-8590.
23. Deng ZL, Ma Y. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World J Gastroenterol 1998; 4:28-29.
24. Chen X, Wang L, Zhi I, Zhou G, Zhang X, Wang H, et al. The G-3113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther 2005; 78:249-259.
25. Woolridge H, Williams J, Cronin A, Evans N, Steventon GB. CYP1A2 in a smoking and a non-smoking population: correlation of urinary and salivary phenotypic ratios. Drug Metabol Drug Interact 2004; 20:247-261.
26. Dong SX, Ping ZZ, Xiao WZ, Shu CC, Bartoli A, Gatti G, et al. Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. Ther Drug Monit 1998; 20:371-375.
27. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5-flanking region of human CYP1A2 gene: effect on the CYP 1A2 inducibility in humans. J Biochem 1999; 125:803-808.
28. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta-lzaki K, et al. Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 2003; 73:468-474.
29. Chung I, Bresnick E. Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins. Mol Pharmacol 1995; 47:677-685.
30. Chung I, Bresnick E. Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene. Arch Biochem Biophys 1997; 338:220-226.
31. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003; 55:68-76.
32. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483-10488.
33. Woolridge H, Williams J, Cronin A, Evans N, Steventon GB. CYP1A2 in a smoking and a non-smoking population: correlation of urinary and salivary phenotypic ratios. Drug Metabol Drug Interact 2004; 20:247-261.
34. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA. Overexpression of cytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 1996; 24:458-467.
35. Mykkanen H, Zhu H, Salminen E, Juvonen RO, Ling W, Ma J, et al. Fecal and urinary excretion of aflatoxin B(1) metabolites (AFQ(1), AFM(1) and AFB-N(7)-guanine) in young Chinese males. Int J Cancer 2005; 115:879-884.
36. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000; 86:1-7.
37. Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2003; 95:1485-1488.
38. Wojnowski L, Turner PC, Pedersen B, Hustert E, Brockmoller J, Mendy M, et al. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia West Africa. Pharmacogenetics 2004; 14:691-700.
39. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Lee PH, Chen CJ, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma. Int J Cancer 2003; 103:440-444.
40. Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, Goedert JJ, et al. Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev 2005; 14:373-379.